Novel oncolytic viral therapies in patients with thoracic malignancies

Por Ahmad, Zeeshan, Kratzke, Robert A
Publicado no Oncolytic Virother (2016)

Epigenetics of Lung Cancer

Por Langevin, Scott M., Kratzke, Robert A., Kelsey, Karl T.
Publicado em 2014

Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer

Por Edelman, Martin J., Hodgson, Lydia, Wang, Xiaofei, Kratzke, Robert A., Vokes, Everett E.
Publicado em 2012

Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis

Por Xu, Wayne, Banerji, Shantanu, Davie, James R., Kassie, Fekadu, Yee, Douglas, Kratzke, Robert
Publicado em 2013

Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC

Por Patel, Manish R., Jay-Dixon, Joe, Sadiq, Ahad A., Jacobson, Blake A., Kratzke, Robert A.
Publicado em 2013

Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non—Small-Cell Lung Cancer

Por Powell, Steven F., Beitinjaneh, Amer, Tessema, Mathewos, Bliss, Robin L., Kratzke, Robert A., Leach, Joseph, Dudek, Arkadiusz Z.
Publicado no Clin Lung Cancer (2013)

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Ca...

Por Govindan, Ramaswamy, Bogart, Jeffrey, Stinchcombe, Thomas, Wang, Xiaofei, Hodgson, Lydia, Kratzke, Robert, Garst, Jennifer, Brotherton, Timothy, Vokes, Everett E.
Publicado em 2011

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

Por Dudek, Arkadiusz Z., Pang, Herbert, Kratzke, Robert A., Otterson, Gregory A., Hodgson, Lydia, Vokes, Everett E., Kindler, Hedy L.
Publicado em 2012

miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma

Por Xu, Yue, Zheng, Ming, Merritt, Robert E., Shrager, Joseph B., Wakelee, Heather A., Kratzke, Robert A., Hoang, Chuong D.
Publicado no Chest (2013)

A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Por Miller, Antonius A., Pang, Herbert, Hodgson, Lydia, Ramnath, Nithya, Otterson, Gregory A., Kelley, Michael J., Kratzke, Robert A., Vokes, Everett E.
Publicado em 2010

Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell l...

Por Boylan, Alice M., Wang, Xiaofei F, Ko, Richard, Watson, Patricia M, Gu, Lin, Harpole, David, Bueno, Raphael, Kohman, Leslie, Kratzke, Robert
Publicado em 2012

Anti-proliferative effects of Simocyclinone D8 (SD8), a novel catalytic inhibitor of Topoisomerase II

Por Sadiq, Ahad A., Patel, Manish R., Jacobson, Blake A., Escobedo, Marco, Ellis, Keith, Oppegard, Lisa M., Hiasa, Hiroshi, Kratzke, Robert A.
Publicado no Invest New Drugs (2009)

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

Por Jahan, Thierry, Gu, Lin, Kratzke, Robert, Dudek, Arkadiusz, Otterson, Gregory A., Wang, Xiaofei, Green, Mark, Vokes, Everett E., Lee Kindler, Hedy
Publicado no Lung Cancer (2011)

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non-Small Cell Lung Cancer

Por Fujioka, Naomi, Nguyen, Julia, Chen, Chunsheng, Li, Yunfang, Pasrija, Teena, Niehans, Gloria, Johnson, Kathryn N, Gupta, Vinita, Kratzke, Robert A, Gupta, Kalpna
Publicado em 2011

Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo

Por Rousalova, Ilona, Banerjee, Sulagna, Sangwan, Veena, Evenson, Kristen, McCauley, Joel A., Kratzke, Robert, Vickers, Selwyn M., Saluja, Ashok, D’Cunha, Jonathan
Publicado em 2013

Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation

Por Patel, MANISH R., Sadiq, Ahad A., Jay-Dixon, Joe, Jirakulaporn, Tanawat, Jacobson, Blake A., Farassati, Faris, Bitterman, Peter B., Kratzke, Robert A.
Publicado no Int J Oncol (2011)

A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307

Por Dubey, Sarita, Jänne, Pasi A., Krug, Lee, Pang, Herbert, Wang, Xiaofei, Heinze, Robin, Watt, Colleen, Crawford, Jeff, Kratzke, Robert, Vokes, Everett, Kindler, Hedy Lee
Publicado em 2010

Prognostic Significance of Mucin and p53 Expression in Stage IB Non-Small Cell Lung Cancer: A Laboratory Companion Study to CALGB 9633

Por Graziano, Stephen L., Gu, Lin, Wang, Xiaofei, Tatum, Arthur H., Vollmer, Robin T., Strauss, Gary M., Kratzke, Robert, Dudek, Arkadiusz Z., Vokes, Everett E, Green, Mark R.
Publicado em 2010

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from I...

Por Graziano, Stephen L., Lacas, Benjamin, Vollmer, Robin, Kratzke, Robert, Popper, Helmut, Filipits, Martin, Seymour, Lesley, Shepherd, Frances A., Rosell, Rafael, Veillard, Anne Sophie, Taron, Miquel, Pignon, Jean-Pierre
Publicado em 2013

Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide

Por Jacobson, Blake A., Thumma, Saritha C., Jay-Dixon, Joseph, Patel, Manish R., Dubear Kroening, K., Kratzke, Marian G., Etchison, Ryan G., Konicek, Bruce W., Graff, Jeremy R., Kratzke, Robert A.
Publicado em 2013